» Articles » PMID: 35399324

Rapid Emergence of SARS-CoV-2 Omicron Variant is Associated with an Infection Advantage over Delta in Vaccinated Persons

Abstract

Background: The SARS-CoV-2 Omicron variant became a global concern due to its rapid spread and displacement of the dominant Delta variant. We hypothesized that part of Omicron's rapid rise was based on its increased ability to cause infections in persons that are vaccinated compared to Delta.

Methods: We analyzed nasal swab PCR tests for samples collected between December 12 and 16, 2021, in Connecticut when the proportion of Delta and Omicron variants was relatively equal. We used the spike gene target failure (SGTF) to classify probable Delta and Omicron infections. We fitted an exponential curve to the estimated infections to determine the doubling times for each variant. We compared the test positivity rates for each variant by vaccination status, number of doses, and vaccine manufacturer. Generalized linear models were used to assess factors associated with odds of infection with each variant among persons testing positive for SARS-CoV-2.

Findings: For infections with high virus copies (Ct < 30) among vaccinated persons, we found higher odds that they were infected with Omicron compared to Delta, and that the odds increased with increased number of vaccine doses. Compared to unvaccinated persons, we found significant reduction in Delta positivity rates after two (43.4%-49.1%) and three vaccine doses (81.1%), while we only found a significant reduction in Omicron positivity rates after three doses (62.3%).

Conclusion: The rapid rise in Omicron infections was likely driven by Omicron's escape from vaccine-induced immunity.

Funding: This work was supported by the Centers for Disease Control and Prevention (CDC).

Citing Articles

From Emergence to Evolution: Dynamics of the SARS-CoV-2 Omicron Variant in Florida.

Ali S, Giovanetti M, Johnston C, Urdaneta-Paez V, Azarian T, Cella E Pathogens. 2025; 13(12.

PMID: 39770354 PMC: 11679505. DOI: 10.3390/pathogens13121095.


SARS-CoV-2 and Environmental Changes: The Perfect Storm.

Caldarelli M, Rio P, Giambra V, Palucci I, Gasbarrini A, Gambassi G Curr Issues Mol Biol. 2024; 46(11):11835-11852.

PMID: 39590297 PMC: 11592541. DOI: 10.3390/cimb46110703.


Differential responses of SARS-CoV-2 variants to environmental drivers during their selective sweeps.

Smith T, Mishra S, Dorigatti I, Dixit M, Tristem M, Pearse W Sci Rep. 2024; 14(1):13326.

PMID: 38858479 PMC: 11164892. DOI: 10.1038/s41598-024-64044-1.


Inducing Long Lasting B Cell and T Cell Immunity Against Multiple Variants of SARS-CoV-2 Through Mutant Bacteriophage Qβ-Receptor Binding Domain Conjugate.

Tan Z, Yang C, Lin P, Ramadan S, Yang W, Rashidi Z Adv Healthc Mater. 2024; 13(20):e2302755.

PMID: 38733291 PMC: 11305917. DOI: 10.1002/adhm.202302755.


Longitudinal dynamics of the nasopharyngal microbiome in response to SARS-CoV-2 Omicron variant and HIV infection in Kenyan women and their infants.

Zustra A, Leonard V, Holland L, Hu J, Mu T, Holland S Res Sq. 2024; .

PMID: 38699359 PMC: 11065085. DOI: 10.21203/rs.3.rs-4257641/v1.


References
1.
Cameroni E, Bowen J, Rosen L, Saliba C, Zepeda S, Culap K . Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature. 2022; 602(7898):664-670. PMC: 9531318. DOI: 10.1038/s41586-021-04386-2. View

2.
Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J . Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022; 602(7898):671-675. DOI: 10.1038/s41586-021-04389-z. View

3.
Luo C, Morris C, Sachithanandham J, Amadi A, Gaston D, Li M . Infection With the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Delta Variant Is Associated With Higher Recovery of Infectious Virus Compared to the Alpha Variant in Both Unvaccinated and Vaccinated Individuals. Clin Infect Dis. 2021; 75(1):e715-e725. PMC: 8903351. DOI: 10.1093/cid/ciab986. View

4.
Johnson A, Amin A, Ali A, Hoots B, Cadwell B, Arora S . COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence - 25 U.S. Jurisdictions, April 4-December 25, 2021. MMWR Morb Mortal Wkly Rep. 2022; 71(4):132-138. PMC: 9351531. DOI: 10.15585/mmwr.mm7104e2. View

5.
Buchan S, Chung H, Brown K, Austin P, Fell D, Gubbay J . Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes. JAMA Netw Open. 2022; 5(9):e2232760. PMC: 9500552. DOI: 10.1001/jamanetworkopen.2022.32760. View